Profil
Theo H.
Walthie is currently a Member-Supervisory Board at LANXESS Deutschland GmbH.
Previously, he served as Chairman at NBE-Therapeutics AG.
He also held the position of Global Business President-Hydrocarbons & Energy at The Dow Chemical Co. from 1970 to 2007.
Additionally, he was a Member-Supervisory Board at Lanxess AG from 2010 to 2022.
Mr. Walthie obtained his undergraduate degree from Delft University of Technology.
Postes actifs de Theo H. Walthie
| Sociétés | Poste | Début |
|---|---|---|
LANXESS Deutschland GmbH
LANXESS Deutschland GmbH Chemicals: SpecialtyProcess Industries Produces and sells chemicals | Directeur/Membre du Conseil | - |
Anciens postes connus de Theo H. Walthie
| Sociétés | Poste | Fin |
|---|---|---|
| LANXESS AG | Directeur/Membre du Conseil | 25/05/2022 |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Président | 10/08/2020 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | 01/01/2007 |
Formation de Theo H. Walthie
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
The Dow Chemical Co.
The Dow Chemical Co. Chemicals: Major DiversifiedProcess Industries Manufactures specialty additives, modifiers and plastic polyethylene products | Process Industries |
LANXESS AG
LANXESS AG Chemicals: Major DiversifiedProcess Industries Produces and sells specialty additives, intermediaries and engineering materials | Process Industries |
Delft University of Technology
Delft University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LANXESS Deutschland GmbH
LANXESS Deutschland GmbH Chemicals: SpecialtyProcess Industries Produces and sells chemicals | Process Industries |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Health Technology |
















